315 related articles for article (PubMed ID: 19737944)
1. Prevention of progression in monoclonal gammopathy of undetermined significance.
Rajkumar SV
Clin Cancer Res; 2009 Sep; 15(18):5606-8. PubMed ID: 19737944
[TBL] [Abstract][Full Text] [Related]
2. Prevention Is the Best Treatment: The Case for Understanding the Transition from Monoclonal Gammopathy of Undetermined Significance to Myeloma.
Tomasson MH; Ali M; De Oliveira V; Xiao Q; Jethava Y; Zhan F; Fitzsimmons AM; Bates ML
Int J Mol Sci; 2018 Nov; 19(11):. PubMed ID: 30453544
[TBL] [Abstract][Full Text] [Related]
3. Molecular and biologic markers of progression in monoclonal gammopathy of undetermined significance to multiple myeloma.
Mailankody S; Mena E; Yuan CM; Balakumaran A; Kuehl WM; Landgren O
Leuk Lymphoma; 2010 Dec; 51(12):2159-70. PubMed ID: 20958231
[TBL] [Abstract][Full Text] [Related]
4. Monoclonal gammopathy of undetermined significance versus smoldering myeloma: is active surveillance enough?
Jordan WE; Emmons R; Vogl D; Morris GJ
Semin Oncol; 2011 Jun; 38(3):327-34. PubMed ID: 21600358
[No Abstract] [Full Text] [Related]
5. Pathogenesis of monoclonal gammopathy of undetermined significance and progression to multiple myeloma.
Zingone A; Kuehl WM
Semin Hematol; 2011 Jan; 48(1):4-12. PubMed ID: 21232653
[TBL] [Abstract][Full Text] [Related]
6. Monoclonal gammopathy of undetermined significance and smoldering multiple myeloma.
Kyle RA; Rajkumar SV
Curr Hematol Malig Rep; 2010 Apr; 5(2):62-9. PubMed ID: 20425398
[TBL] [Abstract][Full Text] [Related]
7. The spectrum of somatic mutations in monoclonal gammopathy of undetermined significance indicates a less complex genomic landscape than that in multiple myeloma.
Mikulasova A; Wardell CP; Murison A; Boyle EM; Jackson GH; Smetana J; Kufova Z; Pour L; Sandecka V; Almasi M; Vsianska P; Gregora E; Kuglik P; Hajek R; Davies FE; Morgan GJ; Walker BA
Haematologica; 2017 Sep; 102(9):1617-1625. PubMed ID: 28550183
[TBL] [Abstract][Full Text] [Related]
8. Smoldering multiple myeloma and monoclonal gammopathy of undetermined significance.
Bladé J; Rosiñol L
Curr Treat Options Oncol; 2006 May; 7(3):237-45. PubMed ID: 16615879
[TBL] [Abstract][Full Text] [Related]
9. Monoclonal gammopathy and smoldering multiple myeloma: diagnosis, staging, prognosis, management.
Hillengass J; Moehler T; Hundemer M
Recent Results Cancer Res; 2011; 183():113-31. PubMed ID: 21509683
[TBL] [Abstract][Full Text] [Related]
10. From MGUS to Multiple Myeloma, a Paradigm for Clonal Evolution of Premalignant Cells.
van Nieuwenhuijzen N; Spaan I; Raymakers R; Peperzak V
Cancer Res; 2018 May; 78(10):2449-2456. PubMed ID: 29703720
[TBL] [Abstract][Full Text] [Related]
11. Genome-wide association study of monoclonal gammopathy of unknown significance (MGUS): comparison with multiple myeloma.
Thomsen H; Chattopadhyay S; Weinhold N; Vodicka P; Vodickova L; Hoffmann P; Nöthen MM; Jöckel KH; Langer C; Hajek R; Hallmans G; Pettersson-Kymmer U; Ohlsson C; Späth F; Houlston R; Goldschmidt H; Hemminki K; Försti A
Leukemia; 2019 Jul; 33(7):1817-1821. PubMed ID: 30737484
[No Abstract] [Full Text] [Related]
12. Familial monoclonal gammopathy of undetermined significance and multiple myeloma: epidemiology, risk factors, and biological characteristics.
Greenberg AJ; Rajkumar SV; Vachon CM
Blood; 2012 Jun; 119(23):5359-66. PubMed ID: 22354002
[TBL] [Abstract][Full Text] [Related]
13. Subclonal evolution in disease progression from MGUS/SMM to multiple myeloma is characterised by clonal stability.
Dutta AK; Fink JL; Grady JP; Morgan GJ; Mullighan CG; To LB; Hewett DR; Zannettino ACW
Leukemia; 2019 Feb; 33(2):457-468. PubMed ID: 30046162
[TBL] [Abstract][Full Text] [Related]
14. Monoclonal Gammopathy of Undetermined Significance: A Comprehensive Review.
Kaur J; Valisekka SS; Hameed M; Bandi PS; Varma S; Onwughalu CJ; Ibrahim H; Mongia H
Clin Lymphoma Myeloma Leuk; 2023 May; 23(5):e195-e212. PubMed ID: 36966041
[TBL] [Abstract][Full Text] [Related]
15. Upregulation of Dicer is more frequent in monoclonal gammopathies of undetermined significance than in multiple myeloma patients and is associated with longer survival in symptomatic myeloma patients.
Sarasquete ME; Gutiérrez NC; Misiewicz-Krzeminska I; Paiva B; Chillón MC; Alcoceba M; García-Sanz R; Hernández JM; González M; San-Miguel JF
Haematologica; 2011 Mar; 96(3):468-71. PubMed ID: 21160068
[TBL] [Abstract][Full Text] [Related]
16. Quantitative superresolution microscopy reveals differences in nuclear DNA organization of multiple myeloma and monoclonal gammopathy of undetermined significance.
Sathitruangsak C; Righolt CH; Klewes L; Tammur P; Ilus T; Tamm A; Punab M; Olujohungbe A; Mai S
J Cell Biochem; 2015 May; 116(5):704-10. PubMed ID: 25501803
[TBL] [Abstract][Full Text] [Related]
17. Stromal alterations in patients with monoclonal gammopathy of undetermined significance, smoldering myeloma, and multiple myeloma.
Bogun L; Koch A; Scherer B; Fenk R; Maus U; Bormann F; Köhrer K; Petzsch P; Wachtmeister T; Zukovs R; Dietrich S; Haas R; Schroeder T; Jäger P; Geyh S
Blood Adv; 2024 May; 8(10):2575-2588. PubMed ID: 38241490
[TBL] [Abstract][Full Text] [Related]
18. Prognostic Biomarkers in the Progression From MGUS to Multiple Myeloma: A Systematic Review.
Cosemans C; Oben B; Arijs I; Daniëls A; Declercq J; Vanhees K; Froyen G; Maes B; Mebis J; Rummens JL
Clin Lymphoma Myeloma Leuk; 2018 Apr; 18(4):235-248. PubMed ID: 29506935
[TBL] [Abstract][Full Text] [Related]
19. Monoclonal gammopathy of renal significance: when MGUS is no longer undetermined or insignificant.
Leung N; Bridoux F; Hutchison CA; Nasr SH; Cockwell P; Fermand JP; Dispenzieri A; Song KW; Kyle RA;
Blood; 2012 Nov; 120(22):4292-5. PubMed ID: 23047823
[TBL] [Abstract][Full Text] [Related]
20. Diagnosis and management of smouldering myeloma: A British Society for Haematology Good Practice Paper.
Hughes D; Yong K; Ramasamy K; Stern S; Boyle E; Ashcroft J; Basheer F; Rabin N; Pratt G
Br J Haematol; 2024 Apr; 204(4):1193-1206. PubMed ID: 38393718
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]